Please use this identifier to cite or link to this item:
https://doi.org/10.1371/journal.pone.0001148
Title: | Effects of a flaxseed-derived lignan supplement in type 2 diabetic patients: A randomized, double-blind, cross-over trial | Authors: | Pan A. Sun J. Chen Y. Ye X. Li H. Yu Z. Wang Y. Gu W. Zhang X. Chen X. Wendy D.-W. Liu Y. Lin X. |
Keywords: | enterodiol enterolactone flax essence glucose hemoglobin A1c insulin isoflavone derivative lignan lipid placebo lignan adult aged article China clinical trial controlled clinical trial controlled study crossover procedure diarrhea double blind procedure drug bioavailability drug efficacy drug excretion female flatulence glycemic control human hypercholesterolemia insulin resistance insulin sensitivity linseed lipid blood level major clinical study male nausea non insulin dependent diabetes mellitus randomized controlled trial treatment duration chemistry diet therapy flax middle aged non insulin dependent diabetes mellitus treatment outcome Animalia Aged Cross-Over Studies Diabetes Mellitus, Type 2 Double-Blind Method Female Flax Humans Lignans Male Middle Aged Placebos Treatment Outcome |
Issue Date: | 2007 | Citation: | Pan A., Sun J., Chen Y., Ye X., Li H., Yu Z., Wang Y., Gu W., Zhang X., Chen X., Wendy D.-W., Liu Y., Lin X. (2007). Effects of a flaxseed-derived lignan supplement in type 2 diabetic patients: A randomized, double-blind, cross-over trial. PLoS ONE 2 (11) : e1148. ScholarBank@NUS Repository. https://doi.org/10.1371/journal.pone.0001148 | Rights: | Attribution 4.0 International | Abstract: | Background. Flaxseed consumption has been shown to improve blood lipids in humans and flaxseed-derived lignan has been shown to enhance glycemic control in animals. The study aimed to investigate the effect of a flaxseed-derived lignan supplement on glycemic control, lipid profiles and insulin sensitivity in type 2 diabetic patients. Methodology/Principal Findings. This was a randomized, double-blind, placebo-controlled, cross-over trial and it was conducted between April and December 2006 in Shanghai, China. Seventy-three type 2 diabetic patients with mild hypercholesterolemia were enrolled into the study. Patients were randomized to supplementation with flaxseed-derived lignan capsules (360 mg lignan per day) or placebo for 12 weeks, separated by an 8-week wash-out period. HbA1c, lipid profiles, insulin resistance index and inflammatory factors were measured. Sixty-eight completed the study and were included in the analyses. The lignan supplement significantly improved glycemic control as measured by HbA1c (-0.10�65 % vs. 0.09�52 %, P=0.001) compared to placebo; however no significant changes were observed in fasting glucose and insulin concentrations, insulin resistance and blood lipid profiles. Urinary excretion of lignan metabolites (enterodiol and enterolactone) was significantly higher after the lignan supplement intervention compared to baseline (14.2�.1 vs. 1.2=2.4 ?g/mL, P<0.001). Data also suggested minimal competition between lignan and isoflavones for bioavailability when measured by the excretion concentrations. Conclusions/Significance. Daily lignan supplementation resulted in modest, yet statistically significant improvements in glycemic control in type 2 diabetic patients without apparently affecting fasting glucose, lipid profiles and insulin sensitivity. Further studies are needed to validate these findings and explore the efficacy of lignans on type 2 diabetes. � 2007 Pan et al. | Source Title: | PLoS ONE | URI: | https://scholarbank.nus.edu.sg/handle/10635/161861 | ISSN: | 19326203 | DOI: | 10.1371/journal.pone.0001148 | Rights: | Attribution 4.0 International |
Appears in Collections: | Staff Publications Elements |
Show full item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
10_1371_journal_pone_0001148.pdf | 283 kB | Adobe PDF | OPEN | None | View/Download |
This item is licensed under a Creative Commons License